News
TENX
15.01
-0.27%
-0.04
Weekly Report: what happened at TENX last week (0330-0403)?
Weekly Report · 3d ago
Analysts Offer Insights on Healthcare Companies: Butterfly Network (BFLY) and Tenax Therapeutics (TENX)
TipRanks · 03/30 14:30
Weekly Report: what happened at TENX last week (0323-0327)?
Weekly Report · 03/30 10:08
Tenax Therapeutics (TENX) Price Target Increased by 13.86% to 29.32
NASDAQ · 03/27 03:14
Four new option listings on March 25th
TipRanks · 03/25 12:38
Tenax Therapeutics files $300M mixed securities shelf
TipRanks · 03/24 15:45
Tenax Therapeutics Files Prospectus For Offering $300M Securities
Benzinga · 03/24 15:44
TENAX THERAPEUTICS INC - MAY OFFER UP TO $300 MLN OF SECURITIES - SEC FILING
Reuters · 03/24 15:42
Weekly Report: what happened at TENX last week (0316-0320)?
Weekly Report · 03/23 10:04
Tenax Therapeutics: A Binary Bet With Heavy Downside Likely
Seeking Alpha · 03/18 16:06
Tenax wins bullish view at Cantor ahead of pivotal readout
Seeking Alpha · 03/17 15:57
DraftKings, Eli Lilly downgraded: Wall Street’s top analyst calls
TipRanks · 03/17 13:36
Tenax Therapeutics Price Target Announced at $35.00/Share by Cantor Fitzgerald
Dow Jones · 03/17 12:50
Tenax Therapeutics Initiated at Overweight by Cantor Fitzgerald
Dow Jones · 03/17 12:50
This Ingredion Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Benzinga · 03/17 12:45
Cantor Fitzgerald Initiates Coverage On Tenax Therapeutics with Overweight Rating, Announces Price Target of $35
Benzinga · 03/17 12:40
Cantor starts Tenax at Overweight into Phase 3 readout
TipRanks · 03/17 11:31
Tenax Therapeutics initiated with an Overweight at Cantor Fitzgerald
TipRanks · 03/17 10:10
Tenax Therapeutics Is Maintained at Buy by Guggenheim
Dow Jones · 03/16 12:59
Guggenheim Maintains Buy on Tenax Therapeutics, Raises Price Target to $34
Benzinga · 03/16 12:49
More
Webull provides a variety of real-time TENX stock news. You can receive the latest news about Tenax Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About TENX
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).